Hologic (NASDAQ:HOLX) Releases Q1 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) updated its first quarter 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 1.000-1.030 for the period, compared to the consensus estimate of 1.030. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Stock Performance

Shares of HOLX stock traded up $0.61 during trading hours on Wednesday, reaching $79.41. 903,970 shares of the company’s stock were exchanged, compared to its average volume of 1,588,025. Hologic has a fifty-two week low of $66.93 and a fifty-two week high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $18.44 billion, a P/E ratio of 26.80, a P/E/G ratio of 2.98 and a beta of 0.98. The business has a fifty day moving average price of $81.05 and a 200-day moving average price of $78.11.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the firm earned $0.89 earnings per share. The business’s revenue was up 4.5% on a year-over-year basis. Analysts predict that Hologic will post 4.09 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on HOLX shares. JPMorgan Chase & Co. increased their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday. Mizuho lowered their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday. UBS Group lifted their price target on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday, October 15th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $89.25.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.